Movers and SHAKERS
Cocrystal Pharma Inc. (COCP)
3Q21 Reported With Phase 1 Influenza Trial Expected To Begin
Cocrystal Pharma Inc is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks.
Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
3Q21 Reported. Cocrystal reported a 3Q21 loss of $3.9 million or $(0.04) per share, compared with our expected loss of $3.1 million or $(0.03) per share. The company also confirmed the projected early 2022 start for its Phase 1 Influenza trial, and updated progress on the intranasal and orally administered versions of CDI-45205, a protease inhibitor for SARS-CoV-2 (the virus that causes COVID-19). Cash balance at the end of the quarter was $61.6 million.
Influenza Trial Is Planned For IQ22. The first product from the programs for seasonal and pandemic influenza, CC-42344, is a PB2 inhibitor expected to begin Phase 1 enrollment in early 2022. The trial is being conducted in Australia where the flu season occurs in the middle of the calendar year, with data is expected later in the year. Separately, the Influenza A/B collaboration with Merck could ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.